151 related articles for article (PubMed ID: 35703558)
1. Penicillin plus Ceftriaxone versus Ampicillin plus Ceftriaxone Synergistic Potential against Clinical Enterococcus faecalis Blood Isolates.
Cusumano JA; Khan R; Shah Z; Philogene C; Harrichand A; Huang V
Microbiol Spectr; 2022 Aug; 10(4):e0062122. PubMed ID: 35703558
[TBL] [Abstract][Full Text] [Related]
2. Penicillin-Binding Proteins and Alternative Dual-Beta-Lactam Combinations for Serious Enterococcus faecalis Infections with Elevated Penicillin MICs.
Cusumano JA; Daffinee KE; Ugalde-Silva P; Peti W; Arthur M; Desbonnet C; Rice LB; LaPlante KL; García-Solache M
Antimicrob Agents Chemother; 2023 Feb; 67(2):e0087122. PubMed ID: 36719223
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamics of Ceftaroline plus Ampicillin against Enterococcus faecalis in an
Werth BJ; Shireman LM
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28096164
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of ampicillin and ceftriaxone against ampicillin-susceptible Enterococcus faecium.
Lorenzo MP; Kidd JM; Jenkins SG; Nicolau DP; Housman ST
J Antimicrob Chemother; 2019 Aug; 74(8):2269-2273. PubMed ID: 31050740
[TBL] [Abstract][Full Text] [Related]
5. Meropenem plus Ceftaroline Is Active against Enterococcus faecalis in an
Cusumano JA; Daffinee KE; Piehl EC; García-Solache M; Desbonnet C; Rice LB; LaPlante KL
Antimicrob Agents Chemother; 2022 Oct; 66(10):e0042622. PubMed ID: 36154173
[TBL] [Abstract][Full Text] [Related]
6. Early in vitro development of daptomycin non-susceptibility in high-level aminoglycoside-resistant Enterococcus faecalis predicts the efficacy of the combination of high-dose daptomycin plus ampicillin in an in vivo model of experimental endocarditis.
Pericàs JM; García-de-la-Mària C; Brunet M; Armero Y; García-González J; Casals G; Almela M; Quintana E; Falces C; Ninot S; Fuster D; Llopis J; Marco F; Moreno A; Miró JM;
J Antimicrob Chemother; 2017 Jun; 72(6):1714-1722. PubMed ID: 28204495
[TBL] [Abstract][Full Text] [Related]
7. Differential in vitro susceptibility to ampicillin/ceftriaxone combination therapy among Enterococcus faecalis infective endocarditis clinical isolates.
Westbrook KJ; Chilambi GS; Stellfox ME; Nordstrom HR; Li Y; Iovleva A; Shah NH; Jones CE; Kline EG; Squires KM; Miller WR; Tran TT; Arias CA; Doi Y; Shields RK; Van Tyne D
J Antimicrob Chemother; 2024 Apr; 79(4):801-809. PubMed ID: 38334390
[TBL] [Abstract][Full Text] [Related]
8. [In vitro activity of ampicillin-ceftriaxone against Enterococcus faecalis isolates recovered from invasive infections].
Burguer Moreira N; Nastro M; Vay C; Famiglietti Á; Rodríguez CH
Rev Argent Microbiol; 2016; 48(1):57-61. PubMed ID: 26857425
[TBL] [Abstract][Full Text] [Related]
9. In Vitro Synergism of Penicillin and Ceftriaxone against
Thieme L; Briggs S; Duffy E; Makarewicz O; Pletz MW
Microorganisms; 2021 Oct; 9(10):. PubMed ID: 34683470
[No Abstract] [Full Text] [Related]
10. Efficacy of ampicillin plus ceftriaxone in treatment of experimental endocarditis due to Enterococcus faecalis strains highly resistant to aminoglycosides.
Gavaldà J; Torres C; Tenorio C; López P; Zaragoza M; Capdevila JA; Almirante B; Ruiz F; Borrell N; Gomis X; Pigrau C; Baquero F; Pahissa A
Antimicrob Agents Chemother; 1999 Mar; 43(3):639-46. PubMed ID: 10049280
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of ampicillin combined with ceftriaxone and gentamicin in the treatment of experimental endocarditis due to Enterococcus faecalis with no high-level resistance to aminoglycosides.
Gavaldá J; Onrubia PL; Gómez MT; Gomis X; Ramírez JL; Len O; Rodríguez D; Crespo M; Ruíz I; Pahissa A
J Antimicrob Chemother; 2003 Sep; 52(3):514-7. PubMed ID: 12917251
[TBL] [Abstract][Full Text] [Related]
12. Bactericidal effect of penicillin, ampicillin, and amoxicillin alone and in combination with tobramycin against Enterococcus faecalis as determined by kill-kinetic studies.
Westh H; Frimodt-Møller N; Gutschik E
Infection; 1991; 19(3):170-3. PubMed ID: 1909688
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Enterococcus faecalis clinical isolates with 'penicillin-resistant, ampicillin-susceptible' phenotype as reported by Vitek-2 Compact system.
Tan YE; Ng LS; Tan TY
Pathology; 2014 Oct; 46(6):544-50. PubMed ID: 25158809
[TBL] [Abstract][Full Text] [Related]
14. In vitro study of synergy of ampicillin with ceftriaxone against Listeria monocytogenes.
Lepe JA; Rodríguez-Villodres A; Martín-Gutiérrez G; Luque R; Aznar J
Rev Esp Quimioter; 2019 Oct; 32(5):465-468. PubMed ID: 31515975
[TBL] [Abstract][Full Text] [Related]
15. In vivo synergism of ampicillin, gentamicin, ceftaroline and ceftriaxone against Enterococcus faecalis assessed in the Galleria mellonella infection model.
Thieme L; Hartung A; Makarewicz O; Pletz MW
J Antimicrob Chemother; 2020 Aug; 75(8):2173-2181. PubMed ID: 32357212
[TBL] [Abstract][Full Text] [Related]
16. In vitro synergism and anti-biofilm activity of ampicillin, gentamicin, ceftaroline and ceftriaxone against Enterococcus faecalis.
Thieme L; Klinger-Strobel M; Hartung A; Stein C; Makarewicz O; Pletz MW
J Antimicrob Chemother; 2018 Jun; 73(6):1553-1561. PubMed ID: 29506271
[TBL] [Abstract][Full Text] [Related]
17. Fractional maximal effect method for in vitro synergy between amoxicillin and ceftriaxone and between vancomycin and ceftriaxone against Enterococcus faecalis and penicillin-resistant Streptococcus pneumoniae.
Desbiolles N; Piroth L; Lequeu C; Neuwirth C; Portier H; Chavanet P
Antimicrob Agents Chemother; 2001 Dec; 45(12):3328-33. PubMed ID: 11709304
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the novel combination of daptomycin plus ceftriaxone against vancomycin-resistant enterococci in an in vitro pharmacokinetic/pharmacodynamic simulated endocardial vegetation model.
Hall Snyder A; Werth BJ; Barber KE; Sakoulas G; Rybak MJ
J Antimicrob Chemother; 2014 Aug; 69(8):2148-54. PubMed ID: 24777900
[TBL] [Abstract][Full Text] [Related]
19. Outpatient parenteral antimicrobial therapy in Enterococcus faecalis infective endocarditis.
Gil-Navarro MV; Lopez-Cortes LE; Luque-Marquez R; Galvez-Acebal J; de Alarcon-Gonzalez A
J Clin Pharm Ther; 2018 Apr; 43(2):220-223. PubMed ID: 29030859
[TBL] [Abstract][Full Text] [Related]
20. Changes in the treatment of Enterococcus faecalis infective endocarditis in Spain in the last 15 years: from ampicillin plus gentamicin to ampicillin plus ceftriaxone.
Pericas JM; Cervera C; del Rio A; Moreno A; Garcia de la Maria C; Almela M; Falces C; Ninot S; Castañeda X; Armero Y; Soy D; Gatell JM; Marco F; Mestres CA; Miro JM;
Clin Microbiol Infect; 2014 Dec; 20(12):O1075-83. PubMed ID: 25040215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
